18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response

被引:98
作者
Gillham, C. M.
Lucey, J. A.
Keogan, M.
Duffy, G. J.
Malik, V.
Raouf, A. A.
O'Byrne, K.
Hollywood, D.
Muldoon, C.
Reynolds, J. V. [1 ]
机构
[1] St James Hosp, Trinity Coll Dublin, Dept Clin Surg, Trinity Ctr, Dublin 8, Ireland
[2] St James Hosp, Trinity Coll Dublin, Dept Pathol, Dublin 8, Ireland
关键词
oesophageal cancer; positron emission tomography; neoadjuvant chemoradiation; response;
D O I
10.1038/sj.bjc.6603412
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine whether [F-18]-fluorodeoxyglucose-positron emission tomography (FDG-PET) could predict the pathological response in oesophageal cancer after only the first week of neoadjuvant chemoradiation. Thirty-two patients with localised oesophageal cancer had a pretreatment PET scan and a repeat after the first week of chemoradiation. The change in mean maximum standardised uptake value (SUV) and volume of metabolically active tissue (MTV) was compared with the tumour regression grade (TRG) in the final histology. Those who achieved a TRG of 1 and 2 were deemed responders and 3-5 nonresponders. In the responders (28%), the SUV fell from 12.6 (+/- 76.3) to 8.1 (+/- 72.9) after 1 week of chemoradiation (P=0.070). In nonresponders (72%), the results were 9.7 (+/- 5.4) and 7.1 (+/- 3.8), respectively (P=0.003). The MTV in responders fell from 36.6 (+/- 22.7) to 22.3 (+/- 10.4) cm 3 (P=0.180), while in nonresponders, this fell from 35.9 (+/- 36.7) to 31.9 (+/- 52.7) cm(3) (P=0.405). There were no significant differences between responders and nonresponders. The hypothesis that early repeat FDG-PET scanning may predict histomorphologic response was not proven. This may reflect an inflammatory effect of radiation that obscures tumour-specific metabolic changes at this time. This assessment may have limited application in predicting response to multimodal regimens for oesophageal cancer.
引用
收藏
页码:1174 / 1179
页数:6
相关论文
共 32 条
[1]   Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus [J].
Altorki, N ;
Kent, M ;
Ferrara, C ;
Port, J .
ANNALS OF SURGERY, 2002, 236 (02) :177-183
[2]  
Ancona E, 2001, CANCER, V91, P2165, DOI 10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.3.CO
[3]  
2-8
[4]  
[Anonymous], CANCER
[5]  
Bancewicz J, 2002, LANCET, V359, P1727
[6]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[7]   Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma [J].
Brink, I ;
Hentschel, M ;
Bley, TA ;
Walch, A ;
Mix, M ;
Kleimaier, M ;
Moser, E ;
Imdahl, A .
EJSO, 2004, 30 (05) :544-550
[8]  
Brücher BLDM, 2001, ANN SURG, V233, P300
[9]   Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [J].
Burmeister, BH ;
Smithers, BM ;
Gebski, V ;
Fitzgerald, L ;
Simes, RJ ;
Devitt, P ;
Ackland, S ;
Gotley, DC ;
Joseph, D ;
Millar, J ;
North, J ;
Walpole, ET ;
Denham, JW .
LANCET ONCOLOGY, 2005, 6 (09) :659-668
[10]   Whole body 18FDG-PET and the response of esophageal cancer to induction therapy:: Results of a prospective trial [J].
Downey, RJ ;
Akhurst, T ;
Ilson, D ;
Ginsberg, R ;
Bains, MS ;
Gonen, M ;
Koong, H ;
Gollub, M ;
Minsky, BD ;
Zakowski, M ;
Turnbull, A ;
Larson, SM ;
Rusch, V .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) :428-432